AOD-9604 Benefits: What the Evidence Actually Says

AOD-9604 is one of the most searched peptides for fat loss, and most of what you will read about it online is either a sales page or a research supplier. This article sets out what AOD-9604 is, what it was designed to do, what the human studies actually found, the side effects, and where it fits next to better proven options.

The short version: it has a clean safety record and a sensible idea behind it, but the evidence for weight loss is weaker than its reputation.

What is AOD-9604?

AOD-9604 is a modified fragment of human growth hormone. It copies a short section near the end of the growth hormone molecule (amino acids 177 to 191) with one extra amino acid added for stability. Researchers in Australia developed it in the late 1990s after laboratory work suggested this part of growth hormone was responsible for much of its effect on fat.

The goal was to keep the fat burning part of growth hormone and leave out the rest. Full growth hormone raises IGF-1, affects blood sugar and drives tissue growth. AOD-9604 was designed to do none of those things, which is why it is often called an anti-obesity drug fragment.

The benefits people look for

• Fat loss support. In animal studies AOD-9604 increased fat breakdown (lipolysis) and reduced new fat formation, especially in obese animals.
• No rise in IGF-1. Unlike growth hormone and the peptides that release it, AOD-9604 did not raise IGF-1 in human studies.
• No effect on blood sugar. Trials did not find changes in glucose or insulin sensitivity, which full growth hormone can worsen.
• Joint and cartilage interest. Early animal research looked at cartilage repair, and some clinics mention joint support. The human evidence here is very limited.

What the human trials found

AOD-9604 went further in human testing than most peptides you will see marketed online. It was tested in several clinical trials as an obesity treatment, mostly as a daily tablet.

A 12 week trial in about 300 people with obesity reported modest extra weight loss at one dose compared with placebo, roughly a couple of kilograms. That result led to a larger trial of more than 500 people over 24 weeks. In the larger trial, weight loss with AOD-9604 was not meaningfully different from placebo, and in 2007 the developer stopped work on it as an obesity drug.

Those trials did produce useful safety information. Across them, AOD-9604 was well tolerated, side effects looked similar to placebo, and it did not trigger antibodies or change IGF-1. Clinics today usually prescribe it as a small injection under the skin rather than a tablet, and there are no large trials of the injected form for weight loss.

The fair summary is that AOD-9604 is safe in the studies that exist but has not been shown to cause significant weight loss on its own.

Side effects and who should avoid it

Reported side effects are usually mild. With injections, the most common are redness, itching or a small bump at the injection site, and occasional headache. Because it does not raise IGF-1, it avoids some of the concerns that come with growth hormone itself.

It is generally not used in these situations:

• Pregnancy or breastfeeding. There is no safety data.
• Active cancer. As with most peptides, it is avoided while cancer is being treated.
• Tested athletes. The World Anti-Doping Agency treats AOD-9604 as a prohibited substance.

Sourcing is the bigger risk. AOD-9604 is not an FDA approved drug, its status as a compounding ingredient has been under FDA review, and much of what is sold online is labeled research use only, which means it is not made or checked for human injection. We explain how to check a source in where your peptides actually come from, and our wider view is in are peptides safe.

AOD-9604 vs GLP-1 medications and tesamorelin

People comparing fat loss peptides usually land on three options.

• Semaglutide and tirzepatide. FDA approved medications that reduce appetite through GLP-1 (and GIP for tirzepatide). Large trials show substantial weight loss. If weight loss is the main goal, these have by far the strongest evidence. See semaglutide vs tirzepatide.
• Tesamorelin. An FDA approved growth hormone releasing hormone analog that reduces abdominal fat in a specific patient group. It raises IGF-1, so it needs more monitoring.
• AOD-9604. Targets fat metabolism without changing appetite or IGF-1. Gentle and well tolerated, but with modest evidence.

Because AOD-9604 does not suppress appetite, it is sometimes considered for people who are already close to their goal, who cannot use a GLP-1, or alongside a broader plan. No peptide replaces sleep, protein, strength training and a calorie deficit. We cover how stress hormones affect stubborn fat in cortisol and belly fat.

How Recovery Project uses AOD-9604

At RECOVERY PROJECT, AOD-9604 is never prescribed without a physician-led evaluation of your health history, goals and lab work. Our peptide program operates under Dr. Christian Erikson, MD, our Medical Director. If weight loss is your main goal, we will tell you plainly when a GLP-1 medication is the better fit, and when AOD-9604 makes sense as part of a wider plan. Every prescription is filled as a medical grade compounded medication from a licensed pharmacy and followed up over time.

More on the program at AOD-9604 at Recovery Project, and on the alternatives at tirzepatide and tesamorelin. Peptide visits are available in person at our Magnolia clinic or by telehealth anywhere in Texas.